B-Cell Lymphoma

The Waxman Foundation announces $25,000 grant in B-cell lymphoma research

Published in Cancer Weekly, August 16th, 2011

2011 AUG 16 -- NEW YORK-Scott Hiebert, Ph.D., of Vanderbilt University was awarded a $25,000 grant from the Samuel Waxman Cancer Research Foundation to further his research in abnormal BCL6 overexpression, which occurs in a common B-cell lymphoma.

Hiebert and his colleagues at Vanderbilt University have obtained drugs that inhibit HDAC3-another epigenetic control element leading to abnormal gene programs, and ultimately cancer. Scientists believe that by eliminating BCL6, they can turn the genes back on and kill the cancer cells. If the researchers can inhibit HDAC3, they hope to knock out B-cell lymphoma completely.

Hiebert's research...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2011-08-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry